Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Edwards EVOQUE Eos MISCEND Study
NCT02718001 · View on ClinicalTrials.gov ↗
Study Summary
Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
Conditions Studied
Interventions
- DEVICE Edwards EVOQUE Eos Mitral Valve Replacement System
Study Locations (19)
California
- Sutter Mills-Peninsula — Burlingame
- Cedars-Sinai Medical Center — Los Angeles
- Kaiser Permanente San Francisco — San Francisco
Texas
- The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center — Houston
- The Heart Hospital Baylor Plano — Plano
Other
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université Laval — Québec
- St. Michael's Hospital — Toronto
Georgia
- Emory University Hospital/Emory University Hospital Midtown — Atlanta
Illinois
- Northwestern University — Chicago
Indiana
- St. Vincent Heart Center — Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center — Boston
New Jersey
- Morristown Medical Center — Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2015-02-06 |
| Est. Completion | 2033-04-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02718001
The ClinicalTrials.gov registry entry for NCT02718001 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Mitral Valve Regurgitation (Degenerative or Functional) appearing as the primary indexed condition, and to 1 intervention — of which Edwards EVOQUE Eos Mitral Valve Replacement System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02718001 reports 19 study locations spanning 15 distinct geographic areas — top geographies include California, Texas, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02718001 about?
NCT02718001 is a clinical study titled "Edwards EVOQUE Eos MISCEND Study". Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
What is the current status of trial NCT02718001?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 123 participants. The study started on 2015-02-06. Estimated completion is 2033-04-30.
What conditions does trial NCT02718001 study?
This clinical trial studies the following conditions: Mitral Valve Regurgitation (Degenerative or Functional). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02718001?
The interventions under investigation include: Edwards EVOQUE Eos Mitral Valve Replacement System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02718001?
This trial is sponsored by Edwards Lifesciences, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02718001 being conducted?
This trial has 19 study locations across California, Georgia, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.